NKTR — Nektar Therapeutics Share Price
Last trade - 00:00- $255.24m
- -$34.00m
- $90.12m
- 36
- 19
- 84
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.68 | ||
| Price to Tang. Book | 1.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.85% | ||
| Return on Equity | -95.68% | ||
| Operating Margin | -182.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 114.62 | 152.91 | 101.91 | 92.06 | 90.12 | 74.14 | 66.41 | -40.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Directors
- Robert Chess NEC (64)
- Howard Robin CEO (68)
- Gilbert Labrucherie CFO (50)
- Jillian Thomsen SVF (55)
- Mark Wilson SVP (49)
- Brian Kotzin SVP
- John Northcott SVP (43)
- Dimitry Nuyten SVP (45)
- Jonathan Zalevsky OTH (46)
- Roy Whitfield LED (67)
- Jeff Ajer IND (58)
- Diana Brainard IND (50)
- Myriam Curet IND (64)
- Karin Eastham IND (71)
- R. Scott Greer IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 3rd, 1998
- Public Since
- May 3rd, 1994
- No. of Shareholders
- 145
- No. of Employees
- 137
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 183,624,620
- Address
- 455 Mission Bay Boulevard South, SAN FRANCISCO, 94158
- Web
- https://www.nektar.com/
- Phone
- +1 4154825300
- Auditors
- Ernst & Young LLP
Latest News for NKTR
Upcoming Events for NKTR
Q2 2024 Nektar Therapeutics Earnings Release
Q3 2024 Nektar Therapeutics Earnings Release
Similar to NKTR
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
As of Today at 22:15 UTC, shares in Nektar Therapeutics are trading at $1.16. This share price information is delayed by 15 minutes.
Shares in Nektar Therapeutics last closed at $1.16 and the price had moved by +110.91% over the past 365 days. In terms of relative price strength the Nektar Therapeutics share price has outperformed the S&P500 Index by +67.83% over the past year.
The overall consensus recommendation for Nektar Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Nektar Therapeutics does not currently pay a dividend.
Nektar Therapeutics does not currently pay a dividend.
Nektar Therapeutics does not currently pay a dividend.
To buy shares in Nektar Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.16, shares in Nektar Therapeutics had a market capitalisation of $213.00m.
Here are the trading details for Nektar Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NKTR
Based on an overall assessment of its quality, value and momentum Nektar Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nektar Therapeutics is $1.60. That is 37.93% above the last closing price of $1.16.
Analysts covering Nektar Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.81 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nektar Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +98.74%.
As of the last closing price of $1.16, shares in Nektar Therapeutics were trading +37.55% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nektar Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nektar Therapeutics' management team is headed by:
- Robert Chess - NEC
- Howard Robin - CEO
- Gilbert Labrucherie - CFO
- Jillian Thomsen - SVF
- Mark Wilson - SVP
- Brian Kotzin - SVP
- John Northcott - SVP
- Dimitry Nuyten - SVP
- Jonathan Zalevsky - OTH
- Roy Whitfield - LED
- Jeff Ajer - IND
- Diana Brainard - IND
- Myriam Curet - IND
- Karin Eastham - IND
- R. Scott Greer - IND